The components of the regulatory pathway that includes VPS9D1-AS1, miR-532-3p, and HMGA2 may serve as potential targets for novel therapeutic approaches to treat NSCLC. The gene discussed is VPS9D1; the disease is non-small cell lung carcinoma.